Repaglinide    (DrugBank: Repaglinide)

3 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease1
21Mitochondrial disease1
299Cystic fibrosis4

6. Parkinson disease    [ 2,123 clinical trials,   2,046 drugs,   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways]
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,123 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01536366
(ClinicalTrials.gov)
June 200923/1/2012Effect of BIA 9-1067 on the Pharmacokinetics of RepaglinideEffect of BIA 9-1067 on the Pharmacokinetics of Repaglinide in Healthy VolunteersParkinson DiseaseDrug: BIA 9-1067;Drug: RepaglinideBial - Portela C S.A.NULLCompleted18 Years45 YearsAll27Phase 1Portugal

21. Mitochondrial disease    [ 23 clinical trials,   29 drugs,   (DrugBank: 28 drugs),   44 drug target genes,   65 drug target pathways]
Searched query = "Mitochondrial disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 23 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04643249
(ClinicalTrials.gov)
November 10, 202013/11/2020Drug-drug Interaction Study of KL1333 in Healthy SubjectsA Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy SubjectsMitochondrial DiseaseDrug: KL1333;Drug: Flurbiprofen;Drug: Dextromethorphan;Drug: Bupropion;Drug: Midazolam injection;Drug: Omeprazole;Drug: Caffeine;Drug: RepaglinideAbliva ABNULLRecruiting18 Years65 YearsAll14Phase 1United Kingdom

299. Cystic fibrosis    [ 1,592 clinical trials,   1,539 drugs,   (DrugBank: 255 drugs),   81 drug target genes,   162 drug target pathways]
Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 1,592 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00763412
(ClinicalTrials.gov)
November 200629/9/2008Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic FibrosisPilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic FibrosisCystic Fibrosis Related Diabetes;Pancreatic InsufficiencyDrug: placebo;Drug: repaglinideArbelaez, Ana MariaWashington University School of Medicine;National Institutes of Health (NIH);Novo Nordisk A/S;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed12 Years24 YearsAll31N/AUnited States
2NCT00231192
(ClinicalTrials.gov)
October 20053/10/2005Repaglinide for Adolescents With Cystic Fibrosis-Related DiabetesRepaglinide for Adolescents With Cystic Fibrosis-Related DiabetesDiabetesDrug: Repaglinide and InsulinChildren's Hospital of PhiladelphiaNULLWithdrawn12 Years20 YearsBoth0N/AUnited States
3NCT00662714
(ClinicalTrials.gov)
September 200117/4/2008Early Diagnosis of Diabetes Mellitus in Patients With Cystic FibrosisOpen Randomised Prospective Comparative Multi-centre Intervention Study of Patients With Cystic Fibrosis and Early Diagnosed Diabetes MellitusCystic Fibrosis;Diabetes MellitusDrug: Repaglinide;Drug: short-acting Insulin (Actrapid)Mukoviszidose Institut gGmbHNovo Nordisk A/S;Mucoviscidose-ABCF2;Assistance Publique - Hôpitaux de ParisCompleted10 YearsN/ABoth73Phase 3Austria;France;Germany;Italy
4NCT00072904
(ClinicalTrials.gov)
June 200112/11/2003Diabetes Therapy to Improve BMI and Lung Function in CFDiabetes Therapy to Improve BMI and Lung Function in CFCystic Fibrosis;Diabetes MellitusDrug: Insulin Asparte;Drug: RepaglinideNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Cystic Fibrosis Foundation Therapeutics;Novo Nordisk A/SCompleted16 YearsN/ABoth108Phase 3United States;Canada